

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 June 2019

Cumulative for May and June 2019



Contents

Summary of PHARMAC decisions effective 1 June 2019.....	3
News Stories – June 2019 Update	5
New listings.....	5
Labetalol tablets, 100 mg and 200 mg.....	5
Methadone hydrochloride 5 mg tablets	5
Changed listings.....	5
Lamotrigine brand change	5
Dasatinib – changes to access and distribution	6
Stock issues	6
Paracetamol – removing restrictions.....	6
Metoclopramide injection 5 mg per ml, 2 ml ampoule	7
Levodopa with carbidopa (Sinemet).....	7
Acarbose	7
Heparin – listing a 50 injection pack.....	7
Methyldopa.....	7
Mid-cycle listing of celecoxib.....	7
Delistings	8
Dosulepin [dothiepin] hydrochloride	8
News in brief.....	8
Tender News.....	9
Looking Forward	10
Sole Subsidised Supply Products cumulative to June 2019.....	11
New Listings.....	27
Changes to Restrictions, Chemical Names and Presentations	29
Changes to Subsidy and Manufacturer’s Price.....	34
Delisted Items	37
Items to be Delisted	40
Index.....	44

Summary of PHARMAC decisions

EFFECTIVE 1 JUNE 2019

New listings (page 27)

- Acarbose (Accarb) tab 100 mg
- Heparin sodium (Pfizer) inj 25,000 iu per ml, 0.2 ml – S29 and wastage claimable
- Labetalol (Presolol) tab 100 mg and 200 mg – S29 and wastage claimable
- Methyldopa (Methyldopa Mylan) tab 250 mg – S29 and wastage claimable
- Methadone hydrochloride (Methatabs) tab 5 mg – only on a controlled drug form, no patient no-payment payable and safety medicine; prescriber may determine dispensing frequency
- Metoclopramide hydrochloride (Link Healthcare) inj 5 mg per ml, 2 ml ampoule – up to 5 inj available on a PSO, S29 and wastage claimable
- Arsenic trioxide (Baxter) inj 10 mg for ECP, 10 mg OP – PCT only-Specialist

Changes to restrictions (pages 29-31)

- Acarbose (Accarb) tab 50 mg – S29 and wastage removed
- Insulin pen needles (Berpu) 31 g x 6 mm – amended brand name
- Taliglucerase alfa (Eleyso) inj 200 unit vial – Brand switch fee removed
- Para-amino salicylic acid (Paser) grams for oral liq 4 g sachet – amended endorsement criteria
- Protionamide (Peteha) tab 250 mg – amended endorsement criteria
- Paracetamol (Priceline, Paracetamol Pharmacare, Pharmacare and Pharmacy Health) tab 500 mg - blister pack – restrictions removed and stat dispensing reinstated
- Methadone hydrochloride (Methatabs) tab 5 mg - bottle pack – amended presentation description
- Dosulepin [dothiepin] hydrochloride (Dopress) tab 75 mg and cap 25 mg – subsidy by endorsement added
- Dasatinib (Sprycel) tab 20 mg, 50 mg and 70 mg – amended Special Authority, removal of Xpharm and addition of wastage claimable
- Chloroform (PSM) chloroform BP – note added
- Collodion flexible (PSM) collodion flexible – note added

Increased subsidy (pages 34-35)

- Roxithromycin (Arrow-Roxithromycin) tab 150 mg and 300 mg
- Carboplatin (Baxter) inj 1 mg for ECP

Summary of PHARMAC decisions – effective 1 June 2019 (continued)

Decreased subsidy (pages 34-35)

- Insulin pen needles (Berpu) 31 g x 6 mm
- Factor eight inhibitor bypassing fraction (FEIBA NF) inj 500 U
- Emtricitabine with tenofovir disoproxil (Truvada) tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate)
- Efavirenz with emtricitabine and tenofovir disoproxil (Atripla) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate)
- Atazanavir sulphate (Reyataz) cap 150 mg and 200 mg
- Lidocaine [lignocaine] (Cathejell) gel 2%, 10 ml urethral syringe
- Methadone hydrochloride (Methatabs) tab 5 mg-bottle pack
- Levomepromazine maleate (Nozinan) tab 25 mg and 100 mg

News Stories – June 2019 Update

New listings

Labetalol tablets, 100 mg and 200 mg

The Hybloc brand is being discontinued by the supplier, Mylan. We expect stock to be exhausted by September 2019. We are listing Mylan's unregistered Presolol brand of labetalol 100 mg and 200 mg tablets from 1 June 2019. Mylan will notify wholesalers when stock is available. This will be supplied under S29 of the Medicines Act.

A labetalol tab 50 mg presentation of Presolol is not available. Presolol tab 100 mg is not scored, so can't be halved. This means that patients taking labetalol 50 mg tablets will need to transfer to a different treatment.

Methadone hydrochloride 5 mg tablets

We are listing a new blister pack presentation of methadone 5 mg tablet, Methatabs brand from 1 June 2019.

Changed listings

Lamotrigine brand change

A brand change for people using lamotrigine commenced 1 May 2019. People who are not already using the Logem brand of lamotrigine have five months to change to it.

While pharmacists may be already changing their patients to Logem, the Brand Switch Fee doesn't apply until October, when the sole supply period starts. This works with the claiming system. Pharmacists can claim a BSF for each patient they dispense Logem to (once per patient) in the three months following 1 October, regardless of when (or where) the patient changed.

Patient info leaflets are available to order from pharmaonline.co.nz or can be downloaded from our website.

We value the work prescribers and pharmacists do to support their patients through brand changes. There are a range of resources available to support health professionals and patients on the brand change on the My Medicine Has Changed webpage for lamotrigine on the PHARMAC website.



Dasatinib – changes to access and distribution

From 1 June 2019, we are changing the access criteria and distribution for dasatinib (Sprycel) tablets used to treat chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL).

The changes will mean:

- Direct distribution to patients will cease. Dasatinib will now be obtained from community pharmacy, in the same way as other medicines.
- Dasatinib funding will be subject to a standard Special Authority mechanism, with existing patients automatically receiving new numbers.
- People with Ph+ ALL and some people with CML will be eligible for funded dasatinib as a first line treatment, others will need to use it as a second line treatment, after imatinib.

We expect full packs will be able to be used, although wastage is claimable if required.

We have contacted all people currently taking dasatinib and their prescribing haematologists informing them of the changes, including the need for patients to present prescriptions in sufficient time for community pharmacies to order stock. People will get eight weeks' supply delivered on 16 May 2019. They will need a prescription from their haematologist or GP for ongoing supplies. People will start paying the normal pharmacy co-payment.

More information about the changes, including the full access criteria, can be found in the dasatinib notification on our website: <https://www.pharmac.govt.nz/news/notification-2019-05-03-dasatinib/>

Stock issues

Paracetamol – removing restrictions

We are now confident that we have enough stock of paracetamol 500 mg tablets (blister packs) in New Zealand to remove the dispensing restrictions from 1 June 2019.

We have advised wholesalers that they can now remove restrictions on supply to pharmacists. However, we ask that pharmacists order only what is needed at this time to help with maintaining supply in the distribution chain.

We acknowledge the additional work this stock issue has caused for pharmacists and wholesalers.

Metoclopramide injection 5 mg per ml, 2 ml ampoule

We are listing an alternative brand of metoclopramide injection (Link Healthcare) from 1 June 2019 to prevent going out-of-stock. The Link brand is supplied via Section 29.

Levodopa with carbidopa (Sinemet)

Update on this stock issue:

- 100/25 mg immediate release: Stock of Mylan's Kinson brand is available.
- 250/25 mg immediate release: Stock of MSD's Sinemet brand is available.
- 200/50 mg long-acting: Supplies are now exhausted. The alternative is the 100/25 mg long-acting.
- 100/25 mg long-acting: Stock of Mylan's brand is available (listed 1 May 2019)

Thank you for your patience with this stock shortage.

Acarbose

We will list a new 100 mg acarbose tablet (Accarb) from 1 June 2019, due to an ongoing supply issue with the Glucobay brand. Mylan will notify wholesalers when Accarb stock is available. The Accarb 50 mg tablets are now registered, so s29 and wastage will be removed from the listing.

Heparin – listing a 50 injection pack

There is not enough of the 5 injection pack of heparin 5000 iu per ml, 0.2 ml injections. We are listing a 50 injection pack size to avoid an out-of-stock. It will be supplied via Section 29, so wastage will apply.

Methyldopa

We're listing an alternative brand of methyldopa tablets 250 mg due to a potential supply issue. The new brand, Methyldopa Mylan will be supplied via Section 29 in packs of 500 tablets.

Mid-cycle listing of celecoxib

We listed celecoxib (Celebrex) 200 mg capsules from 1 May 2019 due a supply issue with the current brand. This listing was too late to be included in the May Update.

Delistings

Dosulepin [dothiepin] hydrochloride

Mylan is discontinuing supply of dosulepin [dothiepin] hydrochloride (Dopress) 75 mg tablets and 25 mg capsules as these are no longer being made. There are no other registered brands.

We are adding an endorsement to the listings from 1 June 2019, limiting funding to existing patients, so that new patients don't start on this treatment.

Supplies of the 25 mg capsules are expected to be exhausted soon and will be delisted 1 January 2020. Supplies of the 75 mg tablet are expected to be exhausted early 2020.

We have received expert advice from the Mental Health Subcommittee (of PTAC) that amitriptyline or nortriptyline could be considered as an alternative. Prescribers could also consider imipramine or mirtazapine.

News in brief

- **Hydrogen peroxide** (Crystaderm) crm 1%, 10 g OP – delisting delayed until further notice.
- **Para-amino salicylic acid** and **protionamide** – minor changes to wording of restriction to align with other antituberculotics



Tender News

Sole Subsidised Supply changes – effective 1 July 2019

Chemical Name	Presentation; Pack size	Sole Subsidised Supply brand (and supplier)
Abacavir sulphate	Tab 300 mg; 60 tab	Ziagen (GlaxoSmithKline)
Abacavir sulphate with lamivudine	Tab 600 mg with lamivudine 300 mg; 60 tab	Kivexa (GlaxoSmithKline)
Baclofen	Inj 2 mg per ml, 5 ml ampoule; 5 inj	Medsurge (Medsurge)
Emtricitabine	Cap 200 mg; 30 cap	Emtriva (Gilead)
Epoetin alfa	Inj 1,000 iu in 0.5 ml, syringe; 6 inj	Binocrit (Novartis)
Epoetin alfa	inj 2,000 iu in 1 ml, syringe; 6 inj	Binocrit (Novartis)
Epoetin alfa	inj 3,000 iu in 0.3 ml, syringe; 6 inj	Binocrit (Novartis)
Epoetin alfa	inj 4,000 iu in 0.4 ml, syringe; 6 inj	Binocrit (Novartis)
Epoetin alfa	inj 5,000 iu in 0.5 ml, syringe; 6 inj	Binocrit (Novartis)
Epoetin alfa	inj 6,000 iu in 0.6 ml, syringe; 6 inj	Binocrit (Novartis)
Epoetin alfa	inj 8,000 iu in 0.8 ml, syringe; 6 inj	Binocrit (Novartis)
Epoetin alfa	inj 10,000 iu in 1 ml, syringe; 6 inj	Binocrit (Novartis)
Epoetin alfa	inj 40,000 iu in 1 ml, syringe; 1 inj	Binocrit (Novartis)
Etoposide	Cap 50 mg; 20 cap	Vepesid (Bristol-Myers Squibb)
Etoposide	Cap 100 mg; 10 cap	Vepesid (Bristol-Myers Squibb)
Glycerin with sodium saccharin	Suspension; 473 ml bottle	Ora-Sweet SF (Midwest)
Glycerin with sucrose	Suspension; 473 ml bottle	Ora-Sweet (Midwest)
Latanoprost	Eye drops 0.005%; 2.5 ml OP	Teva (Teva)
Lidocaine [lignocaine] hydrochloride	Inj 1%, 20 ml vial; 5 inj	Lidocaine-Clarix (Baxter)
Lidocaine [lignocaine] hydrochloride	Inj 2%, 20 ml vial; 5 inj	Lidocaine-Clarix (Baxter)
Mercaptopurine	Tab 50 mg; 25 tab	Puri-nethol (Aspen Pharma)
Methylcellulose	Powder; 100 g	Midwest (Midwest)
Methylcellulose	Suspension; 473 ml bottle	Ora Plus (Midwest)
Methylcellulose with glycerin and sodium saccharin	Suspension; 473 ml bottle	Ora Blend SF (Midwest)
Methylcellulose with glycerin and sucrose	Suspension; 473 ml bottle	Ora Blend (Midwest)
Methyl hydroxybenzoate	Powder; 25 g	Midwest (Midwest)
Moclobemide	Tab 150 mg; 60 tab	Aurorix (Mylan)
Moclobemide	Tab 300 mg; 60 tab	Aurorix (Mylan)
Ritonavir	Tab 100 mg; 30 tab	Norvir (Abbvie)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.

Decisions for implementation 1 July 2019

- Abacavir sulphate (Ziagen) tab 300 mg – price and subsidy decrease
- Abacavir sulphate with lamivudine (Kivexa) tab 600 mg with lamivudine 300 mg – price and subsidy decrease
- Atomoxetine (Generic Partners) cap 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg – new listing and Special Authority removed
- Flecainide acetate (Flecainide Controlled Release Teva) cap long-acting 100 mg and 200 mg – new listing
- Interferon beta-1-alpha inj 6 million iu prefilled syringe (Avonex) and injection 6 million iu per 0.5 ml pen injector (Avonex Pen) – addition of no patient co-payment payable and removal of Xpharm
- Interferon beta-1-beta (Betaferon) inj 8 million iu per 1 ml – addition of no patient no-payment payable and removal of Xpharm
- Zoledronic acid (Aclasta) inj 5 mg per ml, 100 ml vial – price and subsidy decrease

Possible decisions for future implementation 1 July 2019

- Etanercept (Enbrel) inj 25 mg, 50 mg autoinjector and 50 mg prefilled syringe – amended Special Authority criteria

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Acarbose	Tab 50 mg & 100 mg	Glucobay	2021
Acetazolamide	Tab 250 mg	Diamox	2020
Acetylcysteine	Inj 200 mg per ml, 10 ml ampoule	DBL Acetylcysteine	2021
Aciclovir	Eye oint 3%, 4.5 g OP Tab dispersible 200 mg, 400 mg & 800 mg	VirusPOS Lovir	2019
Acitretin	Cap 10 mg & 25 mg	Novatretin	2020
Adult diphtheria and tetanus vaccine	Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml	ADT Booster	2020
Alendronate sodium	Tab 70 mg	Fosamax	2022
Alendronate sodium with colecalciferol	Tab 70 mg with colecalciferol 5,600	Fosamax Plus	2022
Alfacalcidol	Cap 0.25 mcg & 1 mcg Oral drops 2 mcg per ml, 20 ml OP	One-Alpha	2020
Allopurinol	Tab 100 mg & 300 mg	DP-Allopurinol	2020
Aminophylline	Inj 25 mg per ml, 10 ml ampoule	DBL Aminophylline	2020
Amiodarone hydrochloride	Inj 50 mg per ml, 3 ml ampoule Tab 100 mg & 200 mg	Lodi Cordarone X	2019
Amisulpride	Tab 100 mg, 200 mg & 400 mg Oral liq 100 mg per ml	Sulprix Solian	2019
Amitriptyline	Tab 10 mg, 25 mg and 50 mg	Arrow-Amitriptyline	2020
Amlodipine	Tab 2.5 mg, 5 mg & 10 mg	Apo-Amlodipine	2020
Amorolfine	Nail soln 5%, 5 ml OP	MycosNail	2020
Amoxicillin	Grans for oral liq 125 mg per 5 ml, 100 ml OP Grans for oral liq 250 mg per 5 ml, 100 ml OP Inj 250 mg, 500 mg and 1 g vials Cap 250 mg & 500 mg	Alphamox 125 Alphamox 250 Ibiamox Apo-Amoxi	2020 2020 2019
Amoxicillin with clavulanic acid	Tab 500 mg with clavulanic acid 125 mg Grans for oral liq amoxicillin 50 mg with clavulanic acid 12.5 mg per ml, 100 ml OP	Augmentin Curam	2020 2019
Anastrozole	Tab 1 mg	Rolin	2020
Aprepitant	Cap 2 x 80 mg and 1 x 125 mg, 3 OP	Emend Tri-Pack	2021
Aqueous cream	Crn	Boucher	2021
Aripiprazole	Tab 5 mg, 10 mg, 15 mg, 20 mg & 30 mg	Aripiprazole Sandoz	2021
Ascorbic acid	Tab 100 mg	Cvite	2019
Aspirin	Tab 100 mg Tab dispersible 300 mg	Ethics Aspirin EC Ethics Aspirin	2019

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Atenolol	Tab 50 mg & 100 mg	Mylan Atenolol	2021
Atorvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Lorstat	2021
Atropine sulphate	Inj 600 mcg per ml, 1 ml ampoule Eye drops 1%, 15 ml OP	Martindale Atropt	2021 2020
Azathioprine	Tab 25 mg & 50 mg Inj 50 mg vial	Imuran	2019
Azithromycin	Grans for oral liq 200 mg per 5 ml (40 mg per ml) Tab 250 mg & 500 mg	Zithromax Apo-Azithromycin	2021
Baclofen	Tab 10 mg	Pacifen	2021
Bendroflumethiazide [bendrofluazide]	Tab 2.5 mg & 5 mg	Arrow-Bendrofluazide	2020
Benzathine benzylpenicillin	Inj 900 mg (1.2 million units) in 2.3 ml syringe	Bicillin LA	2021
Benzylpenicillin sodium [penicillin G]	Inj 600 mg (1 million units) vial	Sandoz	2020
Betahistine dihydrochloride	Tab 16 mg	Vergo 16	2020
Betamethasone dipropionate with calcipotriol	Gel 500 mcg with calcipotriol 50 mcg per g, 60 g OP Oint 500 mcg with calcipotriol 50 mcg per g, 30 g OP	Daivobet	2021
Betamethasone valerate	Lotn 0.1%, 50 ml OP Crn 0.1%, 50 g OP Oint 0.1%, 50 g OP Scalp app 0.1%, 100 ml OP	Betnovate Beta Cream Beta Ointment Beta Scalp	2021
Bezafibrate	Tab 200 mg Tab long-acting 400 mg	Bezalip Bezalip Retard	2021
Bicalutamide	Tab 50 mg	Binarex	2020
Bisacodyl	Tab 5 mg Suppos 10 mg	Lax-Tab Lax-Suppositories	2021
Bisoprolol fumarate	Tab 2.5 mg, 5 mg & 10 mg	Bosvate	2020
Blood glucose diagnostic test meter	Meter with 50 lancets, a lancing device and 10 diagnostic test strips, 1 OP	CareSens N CareSens N POP CareSens N Premier	2022
Blood glucose diagnostic test strip	Test strips, 50 test OP	CareSens N CareSens PRO	2022
Blood ketone diagnostic test strip	Test strips, 10 strip OP	KetoSens	2022
Bosentan	Tab 62.5 mg & 125 mg	Bosentan Dr Reddy's	2021
Brimonidine tartrate	Eye drops 0.2%, 5 ml OP	Arrow-Brimonidine	2020
Budesonide	Metered aqueous nasal spray, 50 mcg per dose & 100 mcg per dose, 200 dose OP	SteroClear	2020

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Bupropion hydrochloride	Tab modified-release 150 mg	Zyban	2020
Buspirone hydrochloride	Tab 5 mg & 10 mg	Orion	2021
Cabergoline	Tab 0.5 mg, 2 & 8 tab	Dostinex	2021
Calamine	Crn, aqueous, BP	healthE Calamine Aqueous Cream BP	2021
Calcipotriol	Oint 50 mcg per g, 100 g OP	Daivonex	2020
Calcitriol	Cap 0.25 mcg & 0.5 mcg	Calcitriol-AFT	2019
Calcium carbonate	Tab 1.25 g (500 mg elemental)	Arrow-Calcium	2020
Candesartan cilexetil	Tab 4 mg, 8 mg, 16 mg & 32 mg	Candestar	2021
Capecitabine	Tab 150 mg & 500 mg	Brinov	2019
Carvedilol	Tab 6.25 mg, 12.5 mg & 25 mg	Carvedilol Sandoz	2020
Cefaclor monohydrate	Grans for oral liq 125 mg per 5 ml Cap 250 mg	Ranbaxy-Cefaclor	2019
Cefalexin	Grans for oral liq 25 mg per ml Grans for oral liq 50 mg per ml Cap 250 mg & 500 mg	Cefalexin Sandoz	2021
		Cephalexin ABM	2019
Cefazolin	Inj 500 mg & 1 g vials	AFT	2020
Ceftriaxone	Inj 500 mg & 1 g vial	DEVA	2019
Celecoxib	Cap 100 mg & 200 mg	Celecoxib Pfizer	2020
Cetirizine hydrochloride	Tab 10 mg	Zista	2019
Cetomacrogol	Crn BP, 500 g	healthE	2021
Cetomacrogol with glycerol	Crn 90% with glycerol 10%, 500 ml OP & 1,000 ml OP	Pharmacy Health Sorbolene with Glycerin	2019
Chloramphenicol	Eye oint 1%, 4 g OP	Chlorsig	2019
Ciclopirox olamine	Nail-soln 8%, 7 ml OP	Apo-Ciclopirox	2021
Cilazapril	Tab 2.5 mg & 5 mg	Apo-Cilazapril	2019
Cilazapril with hydrochlorothiazide	Tab 5 mg with hydrochlorothiazide 12.5 mg	Apo-Cilazapril/ Hydrochlorothiazide	2019
Cinacalcet	Tab 30 mg	Sensipar	2021
Ciprofloxacin	Eye drops 0.3%, 5 ml OP Tab 250 mg, 500 mg & 750 mg	Ciprofloxacin Teva	2020
		Cipflox	
Citalopram hydrobromide	Tab 20 mg	PSM Citalopram	2021
Clarithromycin	Tab 250 mg & 500 mg	Apo-Clarithromycin	2020
Clindamycin	Cap hydrochloride 150 mg Inj phosphate 150 mg per ml, 4 ml ampoule	Clindamycin ABM	2019
		Dalacin C	
Clobetasol propionate	Crn 0.05%, 30 g OP Oint 0.05%, 30 g OP	Dermol	2019

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Clomipramine hydrochloride	Tab 10 mg & 25 mg	Apo-Clomipramine	2021
Clonazepam	Tab 500 mcg & 2 mg	Paxam	2021
Clonidine	Patch 2.5 mg, 100 mcg per day Patch 5 mg, 200 mcg per day Patch 7.5 mg, 300 mcg per day	Mylan	2020
Clonidine hydrochloride	Inj 150 mcg per ml, 1 ml ampoule Tab 25 mcg	Medsurge Clonidine BMN	2021
Clopidogrel	Tab 75 mg	Arrow - Clopid	2019
Clotrimazole	Crn 1%; 20 g OP Vaginal crn 1% with applicators, 35 g OP Vaginal crn 2% with applicators, 20 g OP	Clomazol	2020 2019
Coal tar	Soln BP	Midwest	2019
Codeine phosphate	Tab 15 mg, 30 mg & 60 mg	PSM	2019
Colchicine	Tab 500 mcg	Colgout	2021
Colecalciferol	Cap 1.25 mg (50,000 iu)	Vit.D3	2020
Compound electrolytes	Powder for oral soln	Enerlyte	2019
Compound electrolytes with glucose [dextrose]	Soln with electrolytes (2 x 500 ml), 1,000 ml OP	Pedialyte – bubblegum	2021
Crotamiton	Crn 10%, 20 g OP	Itch-soothe	2021
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2021
Cyproterone acetate	Tab 50 mg & 100 mg	Siterone	2021
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs	Ginet	2020
Darunavir	Tab 400 mg & 600 mg	Prezista	2020
Desferrioxamine mesilate	Inj 500 mg vial	DBL Desferrioxamine Mesylate for Injection BP	2021
Desmopressin acetate	Nasal spray 10 mcg per dose, 6 ml OP Tab 100 mcg & 200 mcg	Desmopressin-Ph&T Minirin	2020 2019
Dexamethasone	Tab 0.5 mg & 4 mg	Dexmethsone	2021
Dexamfetamine sulfate	Tab 5 mg	PSM	2021
Diazepam	Tab 2 mg & 5 mg	Arrow-Diazepam	2020
Diclofenac sodium	Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg	Diclofenac Sandoz Apo-Diclo SR	2021
Digoxin	Tab 62.5 mcg Tab 250 mcg	Lanoxin PG Lanoxin	2019
Dihydrocodeine tartrate	Tab long-acting 60 mg	DHC Continus	2019

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Diltiazem hydrochloride	Cap long-acting 120 mg, 180 mg & 240 mg	Apo-Diltiazem CD	2021
Dimethicone	Crn 10% pump bottle, 500 ml OP	healthE Dimethicone 10%	2021
	Lotn 4%, 200 ml OP	healthE Dimethicone 4% Lotion	2019
	Crn 5%, pump bottle, 500 ml OP	healthE Dimethicone 5%	
Diphtheria, tetanus and pertussis vaccine	Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe	Boostrix	2020
Diphtheria, tetanus, pertussis and polio vaccine	Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe	Infanrix IPV	2020
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	Inj 30IU diphtheria toxoid with 40IU tetanus toxoid, 25mcg pertussis toxoid, 25mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe	Infanrix-hexa	2020
Dipyridamole	Tab long-acting 150 mg	Pytazen SR	2019
Docusate sodium	Tab 50 mg & 120 mg	Coloxyl	2020
Docusate sodium with sennosides	Tab 50 mg with sennosides 8 mg	Laxsol	2021
Domperidone	Tab 10 mg	Pharmacy Health	2021
Donepezil hydrochloride	Tab 5 mg & 10 mg	Donepezil-Rex	2020
Doxazosin	Tab 2 mg & 4 mg	Apo-Doxazosin	2020
Dual blood glucose and blood ketone diagnostic test meter	Meter with 50 lancets, a lancing device and 10 blood glucose diagnostic test strips, 1 OP	CareSens Dual	2022
Emulsifying ointment	Oint BP; 500 g	AFT	2020
Entacapone	Tab 200 mg	Entapone	2021
Eplerenone	Tab 50 mg	Inspra	2021
	Tab 25 mg		
Ergometrine maleate	Inj 500 mcg per ml, 1 ml ampoule	DBL Ergometrine	2020
Escitalopram	Tab 10 mg & 20 mg	Escitalopram-Apotex	2020
Ethinylestradiol	Tab 10 mcg	NZ Medical & Scientific	2021

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Ethinylloestradiol with levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets	Microgynon 20 ED	2020
	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets	Levlen ED	
Exemestane	Tab 25 mg	Pfizer Exemestane	2020
Ezetimibe	Tab 10 mg	Ezetimibe Sandoz	2020
Felodipine	Tab long-acting 5 mg	Felo 5 ER	2021
	Tab long-acting 10 mg	Felo 10 ER	
	Tab long-acting 2.5 mg	Plendil ER	
Fentanyl	Inj 50 mcg per ml, 2 ml ampoule	Boucher and Muir	2021
	Inj 50 mcg per ml, 10 ml ampoule		
	Patch 12.5 mcg per hour	Fentanyl Sandoz	2020
	Patch 25 mcg per hour		
	Patch 50 mcg per hour		
	Patch 75 mcg per hour		
Patch 100 mcg per hour			
Ferrous fumarate	Tab 200 mg (65 mg elemental)	Ferro-tab	2021
Ferrous fumarate with folic acid	Tab 310 mg (100 mg elemental) with folic acid 350 mcg	Ferro-F-Tabs	2021
Ferrous sulphate	Tab long-acting 325 mg (105 mg elemental)	Ferrograd	2021
	Oral liq 30 mg (6 mg elemental) per ml	Ferodan	2019
Finasteride	Tab 5 mg	Ricit	2020
Flucloxacillin	Grans for oral liq 25 mg per ml	AFT	2021
	Grans for oral liq 50 mg per ml		
	Cap 250 mg & 500 mg Inj 1 g vial Inj 250 mg & 500 mg vials	Staphlex Flucil Flucloxin	2020
Fluconazole	Cap 50 mg, 150 mg and 200 mg	Mylan	2020
Fludarabine phosphate	Tab 10 mg	Fludara Oral	2021
Fluorouracil sodium	Crn 5%, 20 g OP	Efudix	2021
Fluoxetine hydrochloride	Cap 20 mg	Arrow-Fluoxetine	2019
	Tab dispersible 20 mg, scored		
Fluticasone propionate	Metered aqueous nasal spray, 50 mcg per dose, 120 dose OP	Flixonase Hayfever & Allergy	2021
Folic acid	Tab 0.8 mg & 5 mg	Apo-Folic Acid	2021
Furosemide [frusemide]	Tab 500 mg	Urex Forte	2021
	Inj 10 mg per ml, 2 ml ampoule	Frusemide-Claris	2019
Gabapentin	Cap 100 mg, 300 mg & 400 mg	Apo-Gabapentin	2021
Gemfibrozil	Tab 600 mg	Lipazil	2019
Glibenclamide	Tab 5 mg	Daonil	2021
Gliclazide	Tab 80 mg	Glizide	2020
Glipizide	Tab 5 mg	Minidiab	2021

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Glucose [dextrose]	Inj 50%, 10 ml ampoule Inj 50%, 90 ml bottle	Biomed	2020
Glycerol	Suppos 3.6 g Liquid	PSM healthE Glycerol BP	2021 2020
Goserelin	Implant 3.6 mg & 10.8 mg syringe	Zoladex	2019
Haemophilus influenzae type B vaccine	Haemophilus influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml	Hiberix	2020
Haloperidol	Tab 500 mcg, 1.5 mg & 5 mg Oral liq 2 mg per ml Inj 5 mg per ml, 1 ml ampoule	Serenace	2019
Heparin sodium	Inj 1,000 iu per ml, 5 ml ampoule Inj 5,000 iu per ml, 5 ml ampoule	Pfizer	2021
Hepatitis A vaccine	Inj 720 ELISA units in 0.5 ml syringe Inj 1440 ELISA units in 1 ml syringe	Havrix Junior Havrix	2020
Hepatitis B recombinant vaccine	Inj 5 mcg per 0.5 ml vial Inj 40 mcg per 1 ml vial	HBvaxPRO	2020
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]	Inj 270 mcg in 0.5 ml syringe	Gardasil 9	2020
Hydrocortisone	Tab 5 mg & 20 mg Powder Crm 1%, 30 g OP Crm 1%, 500 g Inj 100 mg vial	Douglas ABM DermAssist Pharmacy Health Solu-Cortef	2021 2020 2019
Hydrocortisone and paraffin liquid and lanolin	Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%, 250 ml	DP Lotn HC	2020
Hydrocortisone butyrate	Milky emul 0.1%, 100 g OP Oint 0.1%, 100 g OP Scalp lotn 0.1%, 100 ml OP	Locoid Crelo Locoid	2021
Hydrocortisone with miconazole	Crm 1% with miconazole nitrate 2%, 15 g OP	Micreme H	2021
Hydroxocobalamin	Inj 1 mg per ml, 1 ml ampoule	Neo-B12	2021
Hydroxychloroquine	Tab 200 mg	Plaquenil	2021
Hyoscine butylbromide	Tab 10 mg	Buscopan	2020
Ibuprofen	Tab 200 mg	Relieve	2020
Imatinib mesilate	Cap 100 mg & 400 mg	Imatinib-AFT	2020
Imiquimod	Crm 5%, 250 mg sachet	Perrigo	2020
Indapamide	Tab 2.5 mg	Dapa-Tabs	2019

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Ipratropium bromide	Aqueous nasal spray 0.03%, 15 ml OP	Univent	2020
	Nebuliser soln, 250 mcg per ml, 1 ml ampoule		2019
	Nebuliser soln, 250 mcg per ml, 2 ml ampoule		
Isoniazid	Tab 100 mg	PSM	2021
Isoniazid with rifampicin	Tab 100 mg with rifampicin 150 mg & 150 mg with rifampicin 300 mg	Rifinah	2021
Isosorbide mononitrate	Tab 20 mg	Ismo 20	2020
	Tab long-acting 60 mg Tab long-acting 40 mg	Duride Ismo 40 Retard	2019
Isotretinoin	Cap 10 mg & 20 mg	Oratane	2021
	Cap 5 mg		
Ispaghula (psyllium) husk	Powder for oral soln, 500 g OP	Konsyl-D	2020
Itraconazole	Cap 100 mg	Itrazole	2019
Ketoconazole	Shampoo 2%, 100 ml OP	Sebizole	2020
Lactulose	Oral liq 10 g per 15 ml	Laevolac	2019
Lamivudine	Tab 100 mg	Zetlam	2020
Lansoprazole	Cap 15 mg & 30 mg	Lanzol Relief	2021
Leflunomide	Tab 10 mg & 20 mg	Apo-Leflunomide	2020
Letrozole	Tab 2.5 mg	Letrole	2021
Levetiracetam	Oral liq 100 mg per ml, 300 ml OP	Levetiracetam-AFT	2020
Levodopa with carbidopa	Tab 250 mg with carbidopa 25 mg	Sinemet Sinemet CR	2020
	Tab long-acting 200 mg with carbidopa 50 mg		
Levomepromazine hydrochloride	Inj 25 mg per ml, 1 ml ampoule	Wockhardt	2019
Levonorgestrel	Subdermal implant (2 x 75 mg rods)	Jadelle Postinor-1 Mirena	2020
	Tab 1.5 mg		2019
	Intra-uterine system 20 mcg per day		
Lidocaine [lignocaine] hydrochloride	Oral (gel) soln 2%	Mucosoothe	2020
Lisinopril	Tab 5 mg, 10 mg & 20 mg	Ethics Lisinopril	2021
Loperamide hydrochloride	Tab 2 mg	Nodia Diamide Relief	2019
	Cap 2 mg		
Lopinavir with ritanovir	Tab 200 mg with ritonavir 50 mg	Kaletra	2020
Loratadine	Oral liq 1 mg per ml, 120 ml	Lorfast Lorafix	2019
	Tab 10 mg		
Lorazepam	Tab 1 mg & 2.5 mg	Ativan	2021
Losartan potassium	Tab 12.5 mg, 25 mg, 50 mg and 100 mg	Losartan Actavis	2020

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Losartan potassium with hydrochlorothiazide	Tab 50 mg with hydrochlorothiazide 12.5 mg	Arrow-Losartan & Hydrochlorothiazide	2021
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	Molaxole	2020
Magnesium sulphate	Inj 2 mmol per ml, 5 ml ampoule	DBL	2020
Measles, mumps and rubella vaccine	Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml	Priorix	2020
Medroxyprogesterone acetate	Tab 2.5 mg, 5 mg & 10 mg Tab 100 mg Inj 150 mg per ml, 1 ml syringe	Provera Provera HD Depo-Provera	2019
Megestrol acetate	Tab 160 mg	Apo-Megestrol	2021
Meningococcal C conjugate vaccine	Inj 10 mcg in 0.5 ml syringe	Neisvac-C	2020
Meningococcal (Groups A, C, Y and W-135) conjugate vaccine	Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial	Menactra	2020
Metformin hydrochloride	Tab immediate-release 500 mg & 850 mg	Apotex	2021
Methadone hydrochloride	Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	Biodone Biodone Forte Biodone Extra Forte	2021
Methotrexate	Tab 2.5 mg & 10 mg Inj 100 mg per ml, 50 ml vial Inj 25 mg per ml, 2 ml & 20 ml vials	Trexate Methotrexate Ebewe DBL Methotrexate Onco-Vial	2021 2020 2019
Methylprednisolone	Tab 4 mg & 100 mg	Medrol	2021
Methylprednisolone acetate	Inj 40 mg per ml, 1 ml vial	Depo-Medrol	2021
Methylprednisolone (as sodium succinate)	Inj 1 g vial Inj 40 mg, 125 mg & 500 mg vial	Solu-Medrol Solu-Medrol-Act-O-Vial	2021
Metoclopramide hydrochloride	Tab 10 mg	Metoclopramide Actavis 10	2020
Metoprolol succinate	Tab long-acting 23.75 mg, 47.5 mg, 95 mg & 190 mg	Betaloc CR	2020
Metoprolol tartrate	Inj 1 mg per ml, 5 ml vial Tab 50 mg & 100 mg	Metoprolol IV Mylan Apo-Metoprolol	01/02/2022 2021
Miconazole	Oral gel 20 mg per g, 40 g OP	Decozol	2021

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Miconazole nitrate	Crn 2%; 15 g OP Vaginal crm 2% with applicator, 40 g OP	Multichem Micreme	2020
Mirtazapine	Tab 30 mg & 45 mg	Apo-Mirtazapine	2021
Misoprostol	Tab 200 mcg	Cytotec	2019
Mitomycin C	Inj 5 mg vial	Arrow	2019
Mometasone furoate	Crn 0.1%, 15 g OP & 50 g OP Lotn 0.1%, 30 ml OP Oint 0.1%, 15 g OP & 50 g OP	Elocon Alcohol Free Elocon	2021
Montelukast	Tab 4 mg, 5 mg & 10 mg	Apo-Montelukast	2019
Morphine hydrochloride	Oral liq 1 mg per ml, 2 mg per ml, 5 mg per ml & 10 mg per ml	RA-Morph	2021
Morphine sulphate	Tab immediate-release 10 mg & 20 mg Inj 5 mg per ml, 1 ml ampoule Inj 10 mg per ml, 1 ml ampoule Inj 15 mg per ml, 1 ml ampoule Inj 30 mg per ml, 1 ml ampoule Tab long-acting 10 mg, 30 mg, 60 mg & 100 mg	Sevredol DBL Morphine Sulphate Arrow-Morphine LA	2020 2019
Morphine tartrate	Inj 80 mg per ml, 1.5 ml ampoule	DBL Morphine Tartrate	2019
Nadolol	Tab 40 mg & 80 mg	Apo-Nadolol	2021
Naloxone hydrochloride	Inj 400 mcg per ml, 1 ml ampoule	DBL Naloxone Hydrochloride	2021
Naltrexone hydrochloride	Tab 50 mg	Naltraccord	2020
Naproxen	Tab 250 mg Tab 500 mg Tab long-acting 750 mg Tab long-acting 1 g	Noflam 250 Noflam 500 Naprosyn SR 750 Naprosyn SR 1000	2021
Neostigmine metisulfate	Inj 2.5 mg per ml, 1 ml ampoule	AstraZeneca	2020
Nevirapine	Tab 200 mg	Nevirapine Alphapharm	2021
Nicotine	Gum 2 mg & 4 mg (Fruit & Mint) Lozenge 1 mg & 2 mg Patch 7 mg, 14 mg & 21 mg Gum 2 mg & 4 mg (Fruit & Mint) for direct distribution only Lozenge 1 mg & 2 mg for direct distribution only Patch 7 mg, 14 mg & 21 mg for direct distribution only	Habitrol	2020
Nicotinic acid	Tab 50 mg & 500 mg	Apo-Nicotinic Acid	2020
Nifedipine	Tab long-acting 60 mg	Adalat Oros	2020
Norethisterone	Tab 350 mcg	Noriday 28	2021

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Nortriptyline hydrochloride	Tab 10 mg & 25 mg	Norpress	2019
Nystatin	Oral liq 100,000 u per ml, 24 ml OP Vaginal crm 100,000 u per 5 g with applicator(s), 75 g OP	Nilstat	2020
Octreotide	Inj 50 mcg per ml, 1 ml vial Inj 100 mcg per ml, 1 ml vial Inj 500 mcg per ml, 1 ml vial	DBL Octreotide	2020
Oestradiol	Patch 25 mcg per day Patch 50 mcg per day Patch 75 mcg per day Patch 100 mcg per day	Estradot Estradot 50 mcg Estradot Estradot	2019
Oestradiol valerate	Tab 1 mg & 2 mg	Progynova	2021
Oestriol	Crn 1 mg per g with applicator, 15 g OP Pessaries 500 mcg	Ovestin	2020
Oil in water emulsion	Crn	O/W Fatty Emulsion Cream	2021
Olanzapine	Inj 210 mg, 300 mg & 405 mg vial Tab 2.5 mg, 5 mg & 10 mg Tab orodispersible 5 mg & 10 mg	Zyprexa Relprevv Zypine Zypine ODT	2021 2020
Omeprazole	Cap 10 mg Cap 20 mg Cap 40 mg Inj 40 mg ampoule with diluent	Omeprazole actavis 10 Omeprazole actavis 20 Omeprazole actavis 40 Dr Reddy's Omeprazole	2020 2019
Ondansetron	Tab disp 4 mg & 8 mg Tab 4 mg & 8 mg	Ondansetron ODT- DRLA Apo-Ondansetron	2020 2019
Ornidazole	Tab 500 mg	Arrow-Ornidazole	2019
Orphenadrine citrate	Tab 100 mg	Norflex	2021
Oxazepam	Tab 10 mg & 15 mg	Ox-Pam	2020
Oxybutynin	Oral liq 5 mg per 5 ml Tab 5 mg	Apo-Oxybutynin	2019
Oxycodone hydrochloride	Cap immediate-release 5 mg, 10 mg & 20 mg Inj 10 mg per ml, 1 ml & 2 ml ampoule Inj 50 mg per ml, 1 ml ampoule	OxyNorm	2021
Oxytocin	Inj 5 iu per ml, 1 ml ampoule Inj 10 iu per ml, 1 ml ampoule	Oxytocin BNM	2021
Oxytocin with ergometrine maleate	Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml	Syntometrine	2021

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Pancreatic enzyme	Cap pancreatin 150 mg (amylase 8,000 PH Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U)	Creon 10000	2021
	Cap pancreatin 300 mg (amylase 18,000 PH Eur U, lipase 25,000 PH Eur U, total protease 1,000 Ph Eur U)	Creon 25000	
Pamidronate disodium	Inj 3 mg per ml, 10 ml vial Inj 6 mg per ml, 10 ml vial Inj 9 mg per ml, 10 ml vial	Pamisol	2020
Pantoprazole	Tab EC 20 mg & 40 mg	Panzop Relief	2019
Paracetamol	Suppos 500 mg	Gacet	2021
	Suppos 125 mg & 250 mg	Gacet	2021
	Oral liq 250 mg per 5 ml	Paracare Double Strength	2020
	Oral liq 120 mg per 5 ml Tab 500 mg – bottle pack Tab 500 mg – blister pack	Paracare Pharmacare	
Paracetamol with codeine	Tab paracetamol 500 mg with codeine phosphate 8 mg	Paracetamol + Codeine (Relieve)	2020
Paraffin	Oint liquid paraffin 50% with white soft paraffin 50%, 500 ml OP	healthE	2021
Paroxetine	Tab 20 mg	Apo-Paroxetine	2019
Pegylated interferon alpha-2a	Inj 180 mcg prefilled syringe	Pegasys	2020
Perhexiline maleate	Tab 100 mg	Pexsig	2019
Perindopril	Tab 2 mg & 4 mg	Apo-Perindopril	2020
Permethrin	Crm 5%, 30 g OP Lotn 5%, 30 ml OP	Lyderm A-Scabies	2020
Pethidine hydrochloride	Tab 50 mg	PSM	2021
	Inj 50 mg per ml, 1 ml & 2 ml ampoules	DBL Pethidine Hydrochloride	2020
Phenobarbitone	Tab 15 mg & 30 mg	PSM	2021
Phenoxyethylpenicillin (penicillin V)	Cap 250 mg & 500 mg	Cilicaine VK	2021
	Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	AFT	2019
Pindolol	Tab 5 mg, 10 mg & 15 mg	Apo-Pindolol	2021
Pine tar with trolamine laurilsulfate and fluorescein	Soln 2.3% with trolamine laurilsulfate and fluorescein sodium, 500 ml	Pinetarsol	2020
Pioglitazone	Tab 15 mg, 30 mg & 45 mg	Vexazone	2021

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Pneumococcal (PCV10) conjugate vaccine	Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe	Synflorix	2020
Pneumococcal (PPV23) polysaccharide vaccine	Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)	Pneumovax 23	2020
Poliomyelitis vaccine	Inj 80D antigen units in 0.5 ml syringe	IPOL	2020
Poloxamer	Oral drops 10%, 30 ml OP	Coloxyl	2020
Polyvinyl alcohol	Eye drops 1.4%, 15 ml OP Eye drops 3%, 15 ml OP	Vistil Vistil Forte	2019
Potassium chloride	Tab long-acting 600 mg (8 mmol)	Span-K	2021
Potassium citrate	Oral liq 3 mmol per ml, 200 ml OP	Biomed	2021
Potassium iodate	Tab 253 mcg (150 mcg elemental iodine)	NeuroTabs	2020
Pramipexole hydrochloride	Tab 0.25 mg & 1 mg	Ramipex	2019
Pravastatin	Tab 20 mg and 40 mg	Apo-Pravastatin	2020
Prednisolone	Oral liq 5 mg per ml, 30 ml OP	Redipred	2021
Prednisone	Tab 1 mg, 2.5 mg, 5 mg & 20 mg	Apo-Prednisone	2020
Pregabalin	Cap 25 mg, 75 mg, 150 mg & 300 mg	Pregabalin Pfizer	2021
Pregnancy tests - HCG urine	Cassette, 40 test OP	Smith BioMed Rapid Pregnancy Test	2020
Procaine penicillin	Inj 1.5 g in 3.4 ml syringe	Cilicaine	2020
Prochlorperazine	Tab 5 mg	Nausafix	2020
Progesterone	Cap 100 mg	Ultrogestan	2019
Promethazine hydrochloride	Tab 10 mg & 25 mg Oral liq 1 mg per 1 ml Inj 25 mg per ml, 2 ml ampoule	Allersoothe Hospira	2021 2019
Propranolol	Tab 10 mg & 40 mg	Apo-Propranolol	2021
Pyridostigmine bromide	Tab 60 mg	Mestinon	2019
Pyridoxine hydrochloride	Tab 25 mg Tab 50 mg	Vitamin B6 25 Apo-Pyridoxine	2020
Quetiapine	Tab 25 mg, 100 mg, 200 mg & 300 mg	Quetapel	2020
Quinapril	Tab 5 mg Tab 10 mg Tab 20 mg	Arrow-Quinapril 5 Arrow-Quinapril 10 Arrow-Quinapril 20	2021

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg	Accuretic 10	2021
	Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 20	
Ranitidine	Tab 150 mg & 300 mg Oral liq 150 mg per 10 ml	Ranitidine Relief Peptisoothe	2020
Rifabutin	Cap 150 mg	Mycobutin	2019
Rifampicin	Cap 150 mg & 300 mg Oral liq 100 mg per 5 ml	Rifadin	2020
Rifaximin	Tab 550 mg	Xifaxan	2020
Riluzole	Tab 50 mg	Rilutek	2021
Risedronate sodium	Tab 35 mg	Risedronate Sandoz	2019
Risperidone	Tab 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg	Actavis	2020
	Oral liq 1 mg per ml	Risperon	
Rizatriptan	Tab orodispersible 10 mg	Rizamelt	2020
Ropinirole hydrochloride	Tab 0.25 mg, 1 mg, 2 mg & 5 mg	Apo-Ropinirole	2019
Rotavirus vaccine	Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator	Rotarix	2020
Salbutamol	Oral liq 400 mcg per ml	Ventolin Asthalin	2021
	Nebuliser soln, 1 mg per ml, 2.5 ml ampoule		
	Nebuliser soln, 2 mg per ml, 2.5 ml ampoule		
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule	Duolin	2021
Sertraline	Tab 50 mg & 100 mg	Arrow-Sertraline	2019
Sildenafil	Tab 100 mg	Vedafil	2021
	Tab 25 mg & 50 mg		
Simvastatin	Tab 10 mg, 20 mg, 40 mg and 80 mg	Simvastatin Mylan	2020
Sodium chloride	Inj 0.9%, 10 ml ampoule	Pfizer Biomed	2019
	Inj 23.4% (4 mmol/ml), 20 ml ampoule		
	Inj 0.9%, bag; 500 ml & 1,000 ml	Baxter	
Sodium citro-tartrate	Grans eff 4 g sachets	Ural	2020
Sodium fusidate [fusidic acid]	Tab 250 mg	Fucidin	2020
Sodium polystyrene sulphonate	Powder, 454 g OP	Resonium-A	2021
Solifenacin succinate	Tab 5 mg & 10 mg	Solifenacin Mylan	2021

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Somatropin	Inj 5 mg, 10 mg & 15 mg	Omnitrope	2021
Sotalol	Tab 80 mg & 160 mg	Mylan	2019
Spirolactone	Tab 25 mg & 100 mg	Spiractin	2019
Sulfadiazine silver	Crn 1%, 50 g OP	Flamazine	2020
Sulfasalazine	Tab 500 mg Tab EC 500 mg	Salazopyrin Salazopyrin EN	2019
Sumatriptan	Tab 50 mg & 100 mg	Apo-Sumatriptan	2019
Taliglucerase alfa	Inj 200 unit vial	Elelyso	2023
Tamoxifen citrate	Tab 10 mg & 20 mg	Tamoxifen Sandoz	2020
Tamsulosin hydrochloride	Cap 400 mcg	Tamsulosin-Rex	2019
Temazepam	Tab 10 mg	Normison	2020
Temozolomide	Cap 5 mg, 20 mg, 100 mg & 250 mg	Orion Temozolomide	2019
Tenofovir disoproxil	Tab 245 mg (300.6 mg as a succinate)	Tenofovir Disoproxil Teva	2021
Tenoxicam	Tab 20 mg	Tilcotil	2019
Terazosin	Tab 1 mg Tab 2 mg & 5 mg	Actavis Apo-Terazosin	2019
Terbinafine	Tab 250 mg	Deolate	2020
Testosterone cypionate	Inj 100 mg per ml, 10 ml vial	Depo-Testosterone	2020
Testosterone undecanoate	Cap 40 mg	Andriol Testocaps	2021
Tetrabenazine	Tab 25 mg	Motelis	2019
Thiamine hydrochloride	Tab 50 mg	Max Health	2020
Thymol glycerin	Compound, BPC	PSM	2019
Timolol	Eye drops 0.25% & 0.5%, 5 ml OP Eye drops 0.25%, gel forming, 2.5 ml OP Eye drops 0.5%, gel forming, 2.5 ml OP	Arrow-Timolol Timoptol XE	2020 2019
Tobramycin	Inj 40 mg per ml, 2 ml vial	Tobramycin Mylan	2021
Tolcapone	Tab 100 mg	Tasmar	2019
Tramadol hydrochloride	Cap 50 mg Tab sustained-release 100 mg Tab sustained-release 150 mg Tab sustained-release 200 mg	Arrow-Tramadol Tramal SR 100 Tramal SR 150 Tramal SR 200	2020
Tranexamic acid	Tab 500 mg	Cyklolapron	2019
Tretinoin	Crn 0.5 mg per g, 50 g OP	ReTrieve	2021

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to June 2019

Generic Name	Presentation	Brand Name	Expiry Date*
Triamcinolone acetonide	Inj 10 mg per ml, 1 ml ampoule Inj 40 mg per ml, 1 ml ampoule Crm 0.02%, 100 g OP Oint 0.02%, 100 g OP Paste 0.1%, 5 g OP	Kenacort-A 10 Kenacort-A 40 Aristocort Kenalog in Orabase	2020
Trimethoprim	Tab 300 mg	TMP	2021
Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Oral liq 8 mg with sulphamethoxazole 40 mg per ml, 100 ml	Deprim	2020
Tuberculin PPD [Mantoux] test	Inj 5 TU per 0.1 ml, 1 ml vial	Tubersol	2020
Urea	Crm 10%, 100 g OP	healthE Urea Cream	2019
Ursodeoxycholic acid	Cap 250 mg	Ursosan	2020
Valaciclovir	Tab 500 mg & 1,000 mg	Vaclovir	2021
Vancomycin	Inj 500 mg vial	Mylan	2020
Varenicline tartrate	Tab 0.5 mg x 11 and 1 mg x 42, 53 OP Tab 1 mg	Varenicline Pfizer	2021
Varicella vaccine [chickenpox vaccine]	Inj 2000 PFU prefilled syringe plus vial	Varilrix	2020
Venlafaxine	Cap 37.5 mg, 75 mg & 150 mg	Enlafax XR	2020
Vitamin B complex	Tab, strong, BPC	Bplex	2019
Vitamins	Tab (BPC cap strength)	Mvite	2019
Voriconazole	Powder for oral suspension 40 mg per ml Tab 50 mg & 200 mg	Vfend Vttack	2021
Water	Inj 5 ml ampoule Inj 10 ml ampoule	InterPharma Pfizer	2019
Zidovudine [AZT]	Cap 100 mg Oral liq 10 mg per ml, 200 ml OP	Retrovir	2019
Zidovudine [AZT] with lamivudine	Tab 300 mg with lamivudine 150 mg	Alphapharm	2020
Zinc and castor oil	Oint, 500 g	Boucher	2020
Ziprasidone	Cap 20 mg Cap 40 mg, 60 mg & 80 mg	Zusdone	2021
Zopiclone	Tab 7.5 mg	Zopiclone Actavis	2021

June changes are in bold type

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings

Effective 1 June 2019

11	ACARBOSE * Tab 100 mg	20.23	90	✓ Accarb
43	HEPARIN SODIUM Inj 25,000 iu per ml, 0.2 ml	190.00	50	✓ Pfizer \$29 Wastage claimable
49	LABETALOL Tab 100 mg	11.36	100	✓ Presolol \$29
	Tab 200 mg	29.74	100	✓ Presolol \$29 Wastage claimable
51	METHYLDOPA * Tab 250 mg	52.85	500	✓ Methyldopa Mylan \$29 Wastage claimable
122	METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard Formulae Tab 5 mg	1.40	10	✓ Methatabs Note – this is a new blister pack presentation
130	METOCLOPRAMIDE HYDROCHLORIDE * Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	13.56	10	✓ Link Healthcare \$29 Wastage claimable
156	ARSENIC TRIOXIDE – PCT only – Specialist Inj 10 mg for ECP	481.70	10 mg OP	✓ Baxter

Effective 1 May 2019

11	ACARBOSE * Tab 50 mg	10.47	90	✓ Accarb \$29 Wastage claimable
39	EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm] For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
	Inj 250 iu vial.....	612.50	1	✓ Alprolix
	Inj 500 iu vial.....	1,225.00	1	✓ Alprolix
	Inj 1,000 iu vial.....	2,450.00	1	✓ Alprolix
	Inj 2,000 iu vial.....	4,900.00	1	✓ Alprolix
	Inj 3,000 iu vial.....	7,350.00	1	✓ Alprolix

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings – effective 1 May 2019 (continued)

40	RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] – [Xpharm] For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
	Inj 250 iu vial.....	300.00	1	✓ Adynovate
	Inj 500 iu vial.....	600.00	1	✓ Adynovate
	Inj 1,000 iu vial.....	1,200.00	1	✓ Adynovate
	Inj 2,000 iu vial.....	2,400.00	1	✓ Adynovate
43	HEPARIN SODIUM Inj 5,000 iu per ml, 1 ml	28.40	5	✓ Pfizer
78	TETRACOSACTRIN * Inj 250 mcg per ml, 1 ml ampoule	75.00	1	✓ AU Synacthen S29 S29
	Wastage claimable Note – this is a new Pharmacode listing, 2566494.			
94	DOXYCYCLINE * Tab 100 mg – Up to 30 tab available on a PSO	64.43	500	✓ Doxine
97	CYCLOSERINE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician.			
	Cap 250 mg	344.00	60	✓ Cycloclin S29
	Wastage claimable			
109	CELECOXIB Cap 200 mg	2.30	30	✓ Celebrex
122	LEVODOPA WITH CARBIDOPA * Tab long-acting 100 mg with carbidopa 25 mg	23.84	100	✓ Mylan S29
	Wastage claimable			
123	CLOMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency Tab 25 mg	4.73	50	✓ Apo-Clomipramine
124	PHENELZINE SULPHATE * Tab 15 mg	70.80	60	✓ Nardil S29 S29
	Wastage claimable			
155	IRINOTECAN HYDROCHLORIDE – PCT only – Specialist Inj 20 mg per ml, 5 ml vial	71.44	1	✓ Irinotecan Accord S29

Changes to Restrictions, Chemical Names and Presentations

Effective 1 June 2019

11	ACARBOSE (S29 and wastage claimable removed) * Tab 50 mg 10.47 90 ✓ Accarb S29 Wastage claimable
14	INSULIN PEN NEEDLES – Maximum of 100 dev per prescription (amended brand name) * 31 g × 6 mm 9.50 100 ✓ ABM Berpu
31	TALIGLUCERASE ALFA – Special Authority see SA1734 – Retail pharmacy (Brand switch fee removed) Brand switch fee payable (Pharmacode 2561972) Inj 200 unit vial 1,072.00 1 ✓ Elelyso
98	PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist (amended note) a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation of, Specialist must be an infectious disease specialist, clinical microbiologist or respiratory specialist. Grans for oral liq 4 g sachet 280.00 30 ✓ Paser S29
98	PROTIONAMIDE – Retail pharmacy-Specialist (amended note) a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation of, Specialist must be an infectious disease specialist, clinical microbiologist or respiratory specialist. Tab 250 mg 305.00 100 ✓ Peteha S29
121	PARACETAMOL (restrictions removed and stat dispensing reinstated) * Tab 500 mg - blister pack 0.71 100 ✓ Priceline 7.12 1,000 ✓ Paracetamol Pharmacare ✓ Pharmacare ✓ Pharmacy Health a) Maximum of 300 tab per prescription; can be waived by endorsement b) Up to 30 tab available on a PSO c) d) 1) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater who do not use compliance packaging, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long term condition. 2) Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.
122	METHADONE HYDROCHLORIDE (amended presentation description) a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard Formulae Tab 5 mg – bottle pack 1.40 10 ✓ Methatabs Note – this applies to Pharmacode 765503.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions – effective 1 June 2019 (continued)

124	DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Subsidy by endorsement (subsidy by endorsement added)			
	a) Safety medicine; prescriber may determine dispensing frequency			
	b) Subsidy by endorsement – Subsidised for patients who were taking dosulepin [dothiepin] hydrochloride prior to 1 June 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of dosulepin [dothiepin] hydrochloride.			
	Tab 75 mg	11.19	100	✓ Dopress
	Cap 25 mg	6.45	100	✓ Dopress
162	DASATINIB – [Xpharm] – Special Authority see SA1805 0976 – Retail pharmacy (amended Special Authority, removal of Xpharm and addition of wastage claimable)			
	Tab 20 mg	3,774.06	60	✓ Sprycel
	Tab 50 mg	6,214.20	60	✓ Sprycel
	Tab 70 mg	7,692.58	60	✓ Sprycel

Wastage claimable

► **SA1805 0976** Special Authority for Subsidy

Special Authority approved by the GML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz>, and prescriptions should be sent to:

The GML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Faesimile: (04) 916 7574
PO Box 10 254	Email: cmgistcoordinator@pharmac.govt.nz
Wellington	

Special Authority criteria for GML – access by application

- Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- Subsidised for use as monotherapy only.
- Initial approvals valid seven months.
- Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5 × 10⁹/L, platelets > 100 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph + 0-35% metaphases), and absence of extramedullary disease); or
 - no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0 × 10⁹/L, platelets > 20 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph + 0-35% metaphases), and absence of extramedullary disease); or
 - return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver);
- Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph + metaphases.

continued...

Changes to Restrictions – effective 1 June 2019 (continued)

continued...

Initial application only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

1 Both:

1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and

1.2 Maximum dose of 140 mg/day; or

2 Both:

2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and

2.2 Maximum dose of 140 mg/day; or

3 All of the following:

3.1 The patient has a diagnosis of CML in chronic phase; and

3.2 Maximum dose of 100 mg/day; and

3.3 Any of the following:

3.3.1 Patient has documented treatment failure* with imatinib; or

3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or

3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or

3.3.4 Patients is enrolled in the KISS study and requires dasatinib treatment according to the study protocol.**

Renewal only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Lack of treatment failure while on dasatinib*; and

2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and

3 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up <https://www.cancertrialsnz.ac.nz/kiss/>

228 CHLOROFORM (note added)

a) Only in combination

b) Maximum of 100 ml per prescription

c) Only in aspirin and chloroform application.

d) Note: This product is no longer being manufactured by the supplier and will be delisted from the Schedule at a date to be determined.

Chloroform BP.....25.50 500 ml ✓PSM

228 COLLODION FLEXIBLE (note added)

Note: This product is no longer being manufactured by the supplier and will be delisted from the Schedule at a date to be determined.

Collodion flexible19.30 100 ml ✓PSM

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions – effective 1 May 2019

14	<p>INSULIN PUMP – Special Authority see SA1603 – Retail pharmacy (amended presentation description)</p> <p>a) Maximum of 1 dev per prescription b) Only on a prescription c) Maximum of 1 insulin pump per patient each four year period.</p> <p>Min basal rate 0-904 0.1 U/h 4,500.00 1 ✓ Tandem t:slim X2</p>
39	<p>EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – [Xpharm] (amended restriction)</p> <p>For patients with haemophilia, whose funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p> <p>For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p> <p>Inj 1 mg syringe 1,178.30 1 ✓ NovoSeven RT Inj 2 mg syringe 2,356.60 1 ✓ NovoSeven RT Inj 5 mg syringe 5,891.50 1 ✓ NovoSeven RT Inj 8 mg syringe 9,426.40 1 ✓ NovoSeven RT</p>
39	<p>FACTOR EIGHT INHIBITOR BYPASSING FRACTION – [Xpharm] (amended restriction)</p> <p>For patients with haemophilia, whose funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p> <p>For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p> <p>Inj 500 U 1,315.50 1 ✓ FEIBA NF Inj 1,000 U 2,630.00 1 ✓ FEIBA NF Inj 2,500 U 6,575.00 1 ✓ FEIBA NF</p>
39	<p>MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – [Xpharm] (amended restriction)</p> <p>Preferred Brand of recombinant factor VIII for patients with haemophilia from 1 March 2016. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p> <p>For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p> <p>Inj 250 iu prefilled syringe..... 210.00 1 ✓ Xyntha Inj 500 iu prefilled syringe..... 420.00 1 ✓ Xyntha Inj 1,000 iu prefilled syringe..... 840.00 1 ✓ Xyntha Inj 2,000 iu prefilled syringe..... 1,680.00 1 ✓ Xyntha Inj 3,000 iu prefilled syringe..... 2,520.00 1 ✓ Xyntha</p>
40	<p>NONACOG GAMMA, [RECOMBINANT FACTOR IX] – [Xpharm] (amended restriction)</p> <p>For patients with haemophilia, whose funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p> <p>For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.</p> <p>Inj 500 iu vial..... 435.00 1 ✓ RIXUBIS Inj 1,000 iu vial..... 870.00 1 ✓ RIXUBIS Inj 2,000 iu vial..... 1,740.00 1 ✓ RIXUBIS Inj 3,000 iu vial..... 2,610.00 1 ✓ RIXUBIS</p>

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Changes to Restrictions – effective 1 May 2019 (continued)

40	OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – [Xpharm] (amended restriction) Rare Clinical Circumstances Brand of recombinant factor VIII for patients with haemophilia from 1 March 2016. Access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or: The Co-ordinator, Haemophilia Treatments Panel Phone: 0800 023 588 Option 2 PHARMAC PO Box 10 254 Facsimile: (04) 974 4881 Wellington Email: haemophilia@pharmac.govt.nz			
	For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treeters Group in conjunction with the National Haemophilia Management Group.			
	Inj 250 iu vial.....	210.00	1	✓ Advate
	Inj 500 iu vial.....	420.00	1	✓ Advate
	Inj 1,000 iu vial.....	840.00	1	✓ Advate
	Inj 1,500 iu vial.....	1,260.00	1	✓ Advate
	Inj 2,000 iu vial.....	1,680.00	1	✓ Advate
	Inj 3,000 iu vial.....	2,520.00	1	✓ Advate
40	OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – [Xpharm] (amended restriction) Second Brand of recombinant factor VIII for patients with haemophilia from 1 March 2016. Access to funded treatment by application to the Haemophilia Treatments Panel. Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or: The Co-ordinator, Haemophilia Treatments Panel Phone: 0800 023 588 Option 2 PHARMAC PO Box 10 254 Facsimile: (04) 974 4881 Wellington Email: haemophilia@pharmac.govt.nz			
	For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treeters Group in conjunction with the National Haemophilia Management Group.			
	Inj 250 iu vial.....	237.50	1	✓ Kogenate FS
	Inj 500 iu vial.....	475.00	1	✓ Kogenate FS
	Inj 1,000 iu vial.....	950.00	1	✓ Kogenate FS
	Inj 2,000 iu vial.....	1,900.00	1	✓ Kogenate FS
	Inj 3,000 iu vial.....	2,850.00	1	✓ Kogenate FS
43	RIVAROXABAN (PSO restriction added) Tab 15 mg – Up to 14 tab available on a PSO	77.56	28	✓ Xarelto
112	DICLOFENAC SODIUM (reinstate stat dispensing) * Tab long-acting 75 mg.....	22.80	500	✓ Apo-Diclo SR
129	PIZOTIFEN (removal of S29 and wastage) * Tab 500 mcg.....	23.21	100	✓ Sandomigran S29
	Wastage claimable			

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 June 2019

14	INSULIN PEN NEEDLES – Maximum of 100 dev per prescription (↓ subsidy) * 31 g × 6 mm.....	9.50	100	✓ Berpu
39	FACTOR EIGHT INHIBITOR BYPASSING FRACTION – [Xpharm] (↓ subsidy) For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Inj 500 U	1,315.00	1	✓ FEIBA NF
89	ROXITHROMYCIN (↑ subsidy) Tab 150 mg	8.28	50	✓ Arrow-Roxithromycin
	Tab 300 mg	16.33	50	✓ Arrow-Roxithromycin
102	EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Subsidy by endorsement; can be waived by Special Authority see SA1714 (↓ subsidy) Endorsement for treatment of HIV: Prescription is deemed to be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another antiretroviral subsidised under Special Authority SA1651 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber. Note: Emtricitabine with tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA1651. There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the PHARMAC website. Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate)	61.15 (190.02)	30	Truvada
105	EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL – Special Authority see – Retail pharmacy (↓ subsidy) Note: Efavirenz with emtricitabine and tenofovir disoproxil counts as three anti-retroviral medications for the purposes of the anti-retroviral Special Authority Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate)	106.88 (237.52)	30	Atripla
105	ATAZANAVIR SULPHATE – Special Authority see SA1651 – Retail pharmacy (↓ subsidy) Cap 150 mg	141.68 (568.34)	60	Reyataz
	Cap 200 mg	188.91 (757.79)	60	Reyataz
119	LIDOCAINE [LIGNOCAINE] (↓ subsidy) Gel 2%, 10 ml urethral syringe – Subsidy by endorsement	105.00	25	✓ Cathejell
	a) Up to 5 each available on a PSO			
	b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.			

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Changes to Subsidy and Manufacturer's Price – effective 1 June 2019 (continued)

122	METHADONE HYDROCHLORIDE (↓ subsidy)			
	a) Only on a controlled drug form			
	b) No patient co-payment payable			
	c) Safety medicine; prescriber may determine dispensing frequency			
	d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).			
	e) For methadone hydrochloride oral liquid refer Standard Formulae			
	Tab 5 mg – bottle pack.....	1.40	10	✓ Methatabs
131	LEVOMEPRMAZINE MALEATE – Safety medicine; prescriber may determine dispensing frequency (↓ subsidy)			
	Tab 25 mg	16.10	100	✓ Nozinan
	Tab 100 mg	41.75	100	✓ Nozinan
152	CARBOPLATIN – PCT only – Specialist (↑ subsidy)			
	Inj 1 mg for ECP	0.10	1 mg	✓ Baxter

Effective 1 May 2019

39	FACTOR EIGHT INHIBITOR BYPASSING FRACTION – [Xpharm] (↓ subsidy)			
	For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
	Inj 500 U	1,315.50	1	✓ FEIBA NF
	Inj 1,000 U	2,630.00	1	✓ FEIBA NF
	Inj 2,500 U	6,575.00	1	✓ FEIBA NF
40	NONACOG GAMMA, [RECOMBINANT FACTOR IX] – [Xpharm] (↓ subsidy)			
	For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
	Inj 500 iu vial.....	435.00	1	✓ RIXUBIS
	Inj 1,000 iu vial.....	870.00	1	✓ RIXUBIS
	Inj 2,000 iu vial.....	1,740.00	1	✓ RIXUBIS
	Inj 3,000 iu vial.....	2,610.00	1	✓ RIXUBIS
40	OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – [Xpharm] (↓ subsidy)			
	For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
	Inj 250 iu vial.....	210.00	1	✓ Advate
	Inj 500 iu vial.....	420.00	1	✓ Advate
	Inj 1,000 iu vial.....	840.00	1	✓ Advate
	Inj 1,500 iu vial.....	1,260.00	1	✓ Advate
	Inj 2,000 iu vial.....	1,680.00	1	✓ Advate
	Inj 3,000 iu vial.....	2,520.00	1	✓ Advate
44	FILGRASTIM – Special Authority see SA1259 – Retail pharmacy (↓ subsidy)			
	Inj 300 mcg per 0.5 ml prefilled syringe	48.11	5	
		(270.00)		Zarzio
	Inj 480 mcg per 0.5 ml prefilled syringe	80.75	5	
		(432.00)		Zarzio

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price – effective 1 May 2019 (continued)

76	ZOLEDRONIC ACID (↓ subsidy) Inj 4 mg per 5 ml, vial – Special Authority see SA1687 – Retail pharmacy.....	38.03 (550.00)	1	Zometa
94	TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE] (↑ subsidy) * Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO.....	53.96	500	✓ Trisul
100	VALGANCICLOVIR – Special Authority see SA1404 – Retail pharmacy (↓ subsidy) Tab 450 mg	225.00 (1,050.00)	60	Valcyte
109	IBUPROFEN (↓ subsidy) * Oral liq 20 mg per ml.....	1.88	200 ml	✓ Fenpaed
123	OXYCODONE HYDROCHLORIDE (↓ subsidy) a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency			
	Tab controlled-release 5 mg	2.15 (2.63)	20	BNM
	Tab controlled-release 10 mg	2.15 (2.76)	20	BNM
	Tab controlled-release 20 mg	2.15 (4.72)	20	BNM
	Tab controlled-release 40 mg	3.20 (7.69)	20	BNM
	Tab controlled-release 80 mg	10.98 (14.11)	20	BNM
127	LAMOTRIGINE (↓ subsidy) ▲ Tab dispersible 25 mg	2.76	56	✓ Logem
	▲ Tab dispersible 50 mg	3.31	56	✓ Logem
	▲ Tab dispersible 100 mg	4.40	56	✓ Logem
127	LEVETIRACETAM (↓ subsidy) Tab 250 mg	4.99	60	✓ Everet
	Tab 500 mg	8.79	60	✓ Everet
	Tab 750 mg	14.39	60	✓ Everet
	Tab 1,000 mg	18.59	60	✓ Everet
162	VINORELBINE – PCT only – Specialist (↑ subsidy) Inj 1 mg for ECP	1.25	1 mg	✓ Baxter

Delisted Items

Effective 1 June 2019

48	PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Specialist ▲ Tab 150 mg	40.90	50	✓ Rytmonorm
	Note – this delist applies to Pharmacode 791326. A new Pharmacode was listed 1 December 2018.			
53	CHOLESTYRAMINE Powder for oral liq 4 g	19.25 (52.68) (52.68)	50	Questran-Lite Questran-Lite S29 S29
59	HYDROGEN PEROXIDE * Crm 1%	8.56	10 g OP	✓ Crystaderm
	Note – delisting delayed until further notice.			
65	POVIDONE IODINE Skin preparation, povidone iodine 10% with 70% alcohol.....	1.63 (6.04) 8.13 (18.63)	100 ml 500 ml	Orion Orion
88	AZITHROMYCIN – Maximum of 5 days treatment per prescription; can be waived by Special Authority see SA1683 A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised on Special Authority. Tab 250 mg	8.50	6	✓ Zithromax
	Tab 500 mg – Up to 8 tab available on a PSO	0.93	2	✓ Apo-Azithromycin
	Note – the delist for Apo-Azithromycin tab 500 mg applies to Pharmacode 2550059.			
127	LAMOTRIGINE ▲ Tab dispersible 25 mg	2.76	56	✓ Logem
	▲ Tab dispersible 50 mg	3.31	56	✓ Logem
	▲ Tab dispersible 100 mg	4.40	56	✓ Logem
	Note – this delist applies to Pharmacodes 2271761, tab dispersible 25 mg; 2271788, tab dispersible 50 mg and 2271796, tab dispersible 100 mg. New Pharmacodes were listed 1 December 2018.			
130	DOMPERIDONE * Tab 10 mg	2.25 (3.20)	100	Prokinex
131	CLOZAPINE – Hospital pharmacy [HP4] Safety medicine; prescriber may determine dispensing frequency Tab 25 mg	5.69	50	✓ Clozaril
	Note – this delist applies to Pharmacode 454680. A new Pharmacode was listed 1 December 2018.			

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items – effective 1 June 2019 (continued)

133	PIPOTHIAZINE PALMITATE – Subsidy by endorsement a) Safety medicine; prescriber may determine dispensing frequency b) Subsidised for patients who were taking pipothiazine palmitate prior to 1 August 2014 and the prescription or PSO is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of pipothiazine palmitate. Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO 178.48 10 ✓ Piportil Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO 353.32 10 ✓ Piportil
143	PHENOBARBITONE SODIUM – Special Authority see SA1386 – Retail pharmacy Inj 200 mg per ml, 1 ml ampoule 46.20 10 ✓ Martindale S29
149	VARENICLINE TARTRATE – Special Authority see SA1771 – Retail pharmacy a) A maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval, including the starter pack b) Varenicline will not be funded in amounts less than 4 weeks of treatment. Tab 1 mg 13.55 28 (67.74) 27.10 56 Champix (135.48) Tab 0.5 mg × 11 and 1 mg × 14 12.09 25 OP Champix (60.48)
154	GEMCITABINE HYDROCHLORIDE – PCT only – Specialist Inj 200 mg 8.36 1 ✓ Gemcitabine Ebewe
158	EPIRUBICIN HYDROCHLORIDE – PCT only – Specialist Inj 2 mg per ml, 50 ml vial 32.50 1 ✓ Epirubicin Ebewe
162	DASATINIB – Retail pharmacy-Specialist – Special Authority see SA0976 Tab 100 mg 6,214.20 30 ✓ Sprycel
222	LEVOBUNOLOL * Eye drops 0.5% 7.00 5 ml OP ✓ Betagan
224	PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN * Eye oint with soft white paraffin 3.63 3.5 g OP ✓ Refresh Night Time
225	PHARMACY SERVICES May only be claimed once per patient. * Brand switch fee 4.50 1 fee ✓ BSF Elelyso The Pharmacode for BSF Elelyso is 2561972
226	DEFERRIOXAMINE MESILATE * Inj 500 mg vial 51.52 10 ✓ Desferal

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Delisted Items – effective 1 May 2019

11	METFORMIN HYDROCHLORIDE * Tab immediate-release 500 mg.....	8.63 (9.59)	1,000	
	* Tab immediate-release 850 mg.....	7.04 (7.82)	500	Metckek Metformin Mylan
25	PANCREATIC ENZYME Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U)	34.93	100	✓ Creon 10000
	Note – this delist applies to Pharmacode 954322. A new Pharmacode was listed 1 December 2018.			
40	NONACOG GAMMA, [RECOMBINANT FACTOR IX] – [Xpharm] For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Inj 250 iu vial.....	287.50	1	✓ RIXUBIS
45	PHOSPHORUS Tab eff 500 mg (16 mmol)	82.50	100	✓ Phosphate-Sandoz
88	CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA1131 Grans for oral liq 250 mg per 5 ml – Wastage claimable.....	23.12	50 ml	✓ Klacid
	Note – this delist applies to Pharmacode 2494973. A new Pharmacode was listed 1 November 2018.			
106	INTERFERON ALFA-2B – PCT – Retail pharmacy-Specialist a) See prescribing guideline b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist Inj 18 m iu, 1.2 ml multidose pen.....	206.71	1	✓ Intron-A
	Inj 30 m iu, 1.2 ml multidose pen.....	344.52	1	✓ Intron-A
	Inj 60 m iu, 1.2 ml multidose pen.....	689.04	1	✓ Intron-A
110	ALENDRONATE SODIUM – Special Authority see SA0949 – Retail pharmacy * Tab 40 mg	133.00	30	✓ Fosamax
121	PARACETAMOL * Suppos 500 mg	12.40 (12.60)	50	Paracare
223	BIMATOPROST * Eye drops 0.03%	3.30 (3.65)	3 ml OP	Bimatoprost Actavis
246	AMINO ACID FORMULA – Special Authority see SA1219 – Hospital pharmacy [HP3] Powder	53.00	400 g OP	✓ Neocate LCP
	Note – this delist has been delayed until 1 August 2019.			

▲ Three months supply may be dispensed at one time if endorsed
“certified exemption” by the prescriber or pharmacist

* Three months or six months, as
applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 August 2019

44	FILGRASTIM – Special Authority see SA1259 – Retail pharmacy Inj 300 mcg per 0.5 ml prefilled syringe 48.11 (270.00)	5	Zarzio
	Inj 480 mcg per 0.5 ml prefilled syringe 80.75 (432.00)	5	Zarzio
76	ZOLEDRONIC ACID Inj 4 mg per 5 ml, vial – Special Authority see SA1687 – Retail pharmacy..... 38.03 (550.00)	1	Zometa
79	MEDROXYPROGESTERONE ACETATE – See prescribing guideline * Tab 2.5 mg 7.00 Note – delisting delayed until 1 December 2019.	56	✓ Provera
100	VALGANCICLOVIR – Special Authority see SA1404 – Retail pharmacy Tab 450 mg 225.00 (1,050.00)	60	Valcyte
109	IBUPROFEN * Oral liq 20 mg per ml 1.88	200 ml	✓ Fenpaed
123	OXYCODONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency Tab controlled-release 5 mg 2.15 (2.63)	20	BNM
	Tab controlled-release 10 mg 2.15 (2.76)	20	BNM
	Tab controlled-release 20 mg 2.15 (4.72)	20	BNM
	Tab controlled-release 40 mg 3.20 (7.69)	20	BNM
	Tab controlled-release 80 mg 10.98 (14.11)	20	BNM
228	COMPOUND HYDROXYBENZOATE – Only in combination Only in extemporaneously compounded oral mixtures. Soln 34.18	100 ml	✓ David Craig
246	AMINO ACID FORMULA – Special Authority see SA1219 – Hospital pharmacy [HP3] Powder 53.00	400 g OP	✓ Neocate LCP

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	---

Items to be Delisted – effective 1 September 2019

102	EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Subsidy by endorsement; can be waived by Special Authority see SA1714 Endorsement for treatment of HIV: Prescription is deemed to be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another antiretroviral subsidised under Special Authority SA1651 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber. Note: Emtricitabine with tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA1651. There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the PHARMAC website. Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate)	61.15 (190.02)	30	Truvada
105	EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL – Special Authority see SA1651 – Retail pharmacy Note: Efavirenz with emtricitabine and tenofovir disoproxil counts as three anti-retroviral medications for the purposes of the anti-retroviral Special Authority Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate)	106.88 (237.52)	30	Atripla
105	ATAZANAVIR SULPHATE – Special Authority see SA1651 – Retail pharmacy Cap 150 mg	141.68 (568.34)	60	Reyataz
	Cap 200 mg	188.91 (757.79)	60	Reyataz

Effective 1 October 2019

127	LAMOTRIGINE ▲ Tab dispersible 25 mg	20.40 29.09	56	✓ Arrow-Lamotrigine ✓ Lamictal
	▲ Tab dispersible 50 mg	34.70 47.89	56	✓ Arrow-Lamotrigine ✓ Lamictal
	▲ Tab dispersible 100 mg	59.90 79.16	56	✓ Arrow-Lamotrigine ✓ Lamictal

Effective 1 November 2019

40	NONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm] For patients with haemophilia, whose funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.			
	Inj 250 iu vial	310.00	1	✓ BeneFIX
	Inj 500 iu vial	620.00	1	✓ BeneFIX
	Inj 1,000 iu vial	1,240.00	1	✓ BeneFIX
	Inj 2,000 iu vial	2,480.00	1	✓ BeneFIX
	Inj 3,000 iu vial	3,720.00	1	✓ BeneFIX

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted – effective 1 November 2019 (continued)

91	DOXYCYCLINE * Tab 100 mg – Up to 30 tab available on a PSO 6.75 Note – this delist applies to the 250 tab pack	250	✓ Doxine
97	CYCLOSERINE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician. Cap 250 mg 1,294.50	100	✓ King S29
119	LIDOCAINE [LIGNOCAINE] Gel 2%, 10 ml urethral syringe – Subsidy by endorsement 81.50 a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.	10	✓ Pfizer
129	PIZOTIFEN * Tab 500 mcg 23.21 Note – this delist applies to Pharmacode 251666. Pharmacode 2492954 remains listed.	100	✓ Sandomigran

Effective 1 December 2019

79	MEDROXYPROGESTERONE ACETATE – See prescribing guideline * Tab 2.5 mg 7.00	56	✓ Provera
122	METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing frequency d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard Formulae Tab 5 mg – bottle pack 1.40	10	✓ Methatabs

Effective 1 January 2020

78	TETRACOSACTRIN * Inj 250 mcg per ml, 1 ml ampoule 75.00 Note – this delist applies to Pharmacode 2564300.	1	✓ Synacthen S29 S29
124	DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Subsidy by endorsement a) Safety medicine; prescriber may determine dispensing frequency b) Subsidy by endorsement – Subsidised for patients who were taking dosulepin [dothiepin] hydrochloride prior to 1 June 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of dosulepin [dothiepin] hydrochloride. Cap 25 mg 6.45	100	✓ Dopress

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$

Per

Brand or
Generic Mnfr
✓ **fully subsidised**

Items to be Delisted – effective 1 March 2020

110	SODIUM AUROTHIOMALATE			
	Inj 10 mg in 0.5 ml ampoule	76.87	10	✓ Myocrisin
	Inj 20 mg in 0.5 ml ampoule	113.17	10	✓ Myocrisin
	Inj 50 mg in 0.5 ml ampoule	217.23	10	✓ Myocrisin

Effective 1 August 2020

124	DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Subsidy by endorsement			
	a) Safety medicine; prescriber may determine dispensing frequency			
	b) Subsidy by endorsement – Subsidised for patients who were taking dosulepin [dothiepin] hydrochloride prior to 1 June 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of dosulepin [dothiepin] hydrochloride.			
	Tab 75 mg	11.19	100	✓ Dopress

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber or pharmacist

* Three months or six months, as applicable, dispensed all-at-once

Index

Pharmaceuticals and brands

- A**
- Acarbose 27, 29
- Accarb 27, 29
- Advate 33, 35
- Adynovate 28
- Alendronate sodium 39
- Alprolix 27
- Amino acid formula 39, 40
- Apo-Azithromycin 37
- Apo-Clomipramine 28
- Apo-Diclo SR 33
- Arrow-Lamotrigine 41
- Arrow-Roxithromycin 34
- Arsenic trioxide 27
- Atazanavir sulphate 34, 41
- Atripla 34, 41
- AU Synacthen S29 28
- Azithromycin 37
- B**
- BeneFIX 41
- Berpu 29, 34
- Betagan 38
- Bimatoprost 39
- Bimatoprost Actavis 39
- BSF Elelyso 38
- C**
- Carboplatin 35
- Cathejell 34
- Celebrex 28
- Celecoxib 28
- Champix 38
- Chloroform 31
- Cholestyramine 37
- Clarithromycin 39
- Clomipramine hydrochloride 28
- Clozapine 37
- Clozaril 37
- Collodion flexible 31
- Compound hydroxybenzoate 40
- Co-trimoxazole 36
- Creon 10000 39
- Crystaderm 37
- Cyclorin 28
- Cycloserine 28, 42
- D**
- Dasatinib 30, 38
- Desferal 38
- Desferrioxamine mesilate 38
- Diclofenac sodium 33
- Domperidone 37
- Dopress 30, 42, 43
- Dosulepin [Dothiepin] hydrochloride 30, 42, 43
- Dothiepin 30, 42, 43
- Doxine 28, 42
- Doxycycline 28, 42
- E**
- Efavirenz with emtricitabine and tenofovir disoproxil 34, 41
- Eftrenonacog alfa [Recombinant factor IX] 27
- Elelyso 29
- Emtricitabine with tenofovir disoproxil 34, 41
- Epirubicin Ebewe 38
- Epirubicin hydrochloride 38
- Eptacog alfa [Recombinant factor VIIa] 32
- Everet 36
- F**
- Factor eight inhibitor bypassing fraction ... 32, 34, 35
- FEIBA NF 32, 34, 35
- Fenpaed 36, 40
- Filgrastim 35, 40
- Fosamax 39
- G**
- Gemcitabine Ebewe 38
- Gemcitabine hydrochloride 38
- H**
- Heparin sodium 27, 28
- Hydrogen peroxide 37
- I**
- Ibuprofen 36, 40
- Insulin pen needles 29, 34
- Insulin pump 32
- Interferon alfa-2b 39
- Intron-A 39
- Irinotecan Accord 28
- Irinotecan hydrochloride 28
- K**
- King 42
- Klacid 39
- Kogenate FS 33
- L**
- Labetalol 27
- Lamictal 41
- Lamotrigine 36, 37, 41
- Levetiracetam 36
- Levobunolol 38
- Levodopa with carbidopa 28
- Levomepromazine maleate 35
- Lidocaine [Lignocaine] 34, 42
- Lignocaine 34, 42
- Link Healthcare 27
- Logem 36, 37

Index

Pharmaceuticals and brands

M

Medroxyprogesterone acetate.....	40, 42
Metchek.....	39
Metformin hydrochloride.....	39
Metformin Mylan.....	39
Methadone hydrochloride.....	27, 29, 35, 42
Methatabs.....	27, 29, 35, 42
Methyl dopa.....	27
Methyl dopa Mylan.....	27
Metoclopramide hydrochloride.....	27
Moroctocog alfa [Recombinant factor VIII].....	32
Myocrisin.....	43

N

Nardil S29.....	28
Neocate LCP.....	39, 40
Nonacog alfa [Recombinant factor IX].....	41
Nonacog gamma, [Recombinant factor IX].....	32, 35, 39
NovoSeven RT.....	32
Nozinan.....	35

O

Octocog alfa [Recombinant factor VIII] (Advate).....	33, 35
Octocog alfa [Recombinant factor VIII] (Kogenate FS).....	33
Oxycodone hydrochloride.....	36, 40

P

Pancreatic enzyme.....	39
Para-amino salicylic acid.....	29
Paracare.....	39
Paracetamol.....	29, 39
Paracetamol Pharmacare.....	29
Paraffin liquid with soft white paraffin.....	38
Paser.....	29
Peteha.....	29
Pharmacy services.....	38
Phenelzine sulphate.....	28
Phenobarbitone sodium.....	38
Phosphate-Sandoz.....	39
Phosphorus.....	39
Piportil.....	38
Pipothiazine palmitate.....	38
Pizotifen.....	33, 42
Povidone iodine.....	37
Presolol.....	27
Prokinex.....	37

Propafenone hydrochloride.....	37
Protionamide.....	29
Provera.....	40, 42

Q

Questran-Lite.....	37
Questran-Lite S29.....	37

R

Recombinant factor IX.....	27, 32, 35, 39, 41
Recombinant factor VIIa.....	32
Recombinant factor VIII.....	28, 32, 33, 35
Refresh Night Time.....	38
Reyataz.....	34, 41
Rivaroxaban.....	33
RIXUBIS.....	32, 35, 39
Roxithromycin.....	34
Rurioctocog alfa pegol [Recombinant factor VIII].....	28
Rytmonorm.....	37

S

Sandomigran.....	42
Sandomigran S29.....	33
Sodium aurothiomalate.....	43
Sprycel.....	30, 38
Synacthen S29.....	42

T

Taliglucerase alfa.....	29
Tandem t:slim X2.....	32
Tetracosactrin.....	28, 42
Trimethoprim with sulphamethoxazole [Co-trimoxazole].....	36
Trisul.....	36
Truvada.....	34, 41

V

Valcyte.....	36, 40
Valganciclovir.....	36, 40
Varenicline tartrate.....	38
Vinorelbine.....	36

X

Xarelto.....	33
Xyntha.....	32

Z

Zarzio.....	35, 40
Zithromax.....	37
Zoledronic acid.....	36, 40
Zometa.....	36, 40



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990

Fax: 64 4 460 4995

Website: www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1172-9376 (Print)

ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand